Myriad Genetics buy The Goldman Sachs Group, Inc.
Start price
28.01.25
/
50%
€12.20
Target price
28.01.26
€17.25
Performance (%)
-59.34%
Price
07:36
?
Summary
This prediction is currently active. The BUY prediction by The_Goldman_Sachs_Gr for Myriad Genetics is performing very badly with a performance of -59.34%. This prediction currently runs until 28.01.26. The prediction end date can be changed by The_Goldman_Sachs_Gr at any time. The_Goldman_Sachs_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Myriad Genetics | 6.250% | 6.250% |
| iShares Core DAX® | 1.043% | -0.149% |
| iShares Nasdaq 100 | 1.920% | 4.604% |
| iShares Nikkei 225® | 4.840% | 8.328% |
| iShares S&P 500 | 1.567% | 3.310% |
Comments by The_Goldman_Sachs_Gr for this prediction
In the thread Myriad Genetics diskutieren
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $29.00 to $18.00. They now have a "buy" rating on the stock.
Ratings data for MYGN provided by MarketBeat